Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Inventory (2018 - 2025)

Dna X's Inventory history spans 8 years, with the latest figure at $11.0 million for Q3 2025.

  • Quarterly results put Inventory at $11.0 million for Q3 2025, down 11.22% from a year ago — trailing twelve months through Sep 2025 was $11.0 million (down 11.22% YoY), and the annual figure for FY2024 was $10.6 million, up 62.97%.
  • Inventory for Q3 2025 was $11.0 million at Dna X, up from $9.9 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $12.4 million in Q3 2024 to a low of $185000.0 in Q4 2021.
  • The 5-year median for Inventory is $6.5 million (2023), against an average of $7.0 million.
  • The sharpest move saw Inventory plummeted 98.37% in 2021, then skyrocketed 2013.51% in 2022.
  • Year by year, Inventory stood at $185000.0 in 2021, then skyrocketed by 2013.51% to $3.9 million in 2022, then skyrocketed by 66.68% to $6.5 million in 2023, then soared by 62.97% to $10.6 million in 2024, then grew by 3.44% to $11.0 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $11.0 million, $9.9 million, and $8.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.